NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: AbbVie
Conditions: Parkinson's Disease (PD)
Countries: Japan
Parkinson's disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to assess how safe and effective ABBV-951 is in treating participants with Parkinson's disease in real world setting. ABBV-951 is an approved drug being developed for the treatment of PD in Japan. Approximately 250 adult participants over 15 years with a diagnosis of PD who are prescribed ABBV-951 by their physicians will be enrolled in this study across Japan. Participants will receive ABBV-951 as prescribed their physician and followed for 52 weeks. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.
Sex: ALL
Age: 15 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Diagnosed with advanced Parkinson's disease (aPD). * Prescribed ABBV-951 as physicians' decision according to the approved label for treatment of aPD. * Given informed consent (or by her/his legal representative, if it's a requirement from the participating hospital/clinic) for participating this study. Exclusion Criteria: * Prior treatment with ABBV-951 for PD. * Currently participating in interventional clinical trials.
- Matsuyama, Ehime, Japan
- Asahikawa, Hokkaido, Japan
- Hakodate-shi, Hokkaido, Japan
- Ryūgasaki, Ibaraki, Japan
- Tsukuba, Ibaraki, Japan
- Kagoshima, Kagoshima-ken, Japan
- Kyoto, Kyoto, Japan
- Sendai, Miyagi, Japan
- Miyakonojo-shi, Miyazaki, Japan
- Ōtsu, Shiga, Japan
- Mibu, Tochigi, Japan
- Bunkyo-ku, Tokyo, Japan
- Nakano-ku, Tokyo, Japan
- Xiaoping City, Tokyo, Japan
- Kyoto, Japan
- Okayama, Japan
- Toyonaka, Japan